The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).
 
David Berz
Honoraria - AstraZeneca; Caris Life Sciences; EMD Serono; Jazz Pharmaceuticals; Mirati Therapeutics; OncoCyte; Sun Pharma
Consulting or Advisory Role - Jazz Pharmaceuticals; Sun Pharma
Speakers' Bureau - AstraZeneca; Biocept; Boehringer Ingelheim; Caris Life Sciences; EMD Serono; Jazz Pharmaceuticals; Mirati Therapeutics; natera; Novartis; OncoCyte; Sun Pharma
 
Robert M. Jotte
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Roche; Mirati Therapeutics
 
Krishna Kishore Pachipala
Honoraria - Axess Oncology
Consulting or Advisory Role - Axess Oncology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Mark S. Berger
Employment - Actinium Pharmaceuticals; Genprex
Leadership - Actinium Pharmaceuticals; Genprex
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Genprex
Patents, Royalties, Other Intellectual Property - Am holder of patents at Actinium Pharmaceuticals that do not provide for any payments to me; Am holder of patents at Genprex Inc. that do not provide for any payments to me